Since the COVID-19 pandemic, numerous articles have appeared on clinical changes in organs and systems in individuals with humoral immunity to the SARS-CoV-2 virus. However, there is a lack of data on a comprehensive clinical and morphological study of a group of patients with acquired immunity. Objective. To compare lung pathology with humoral immunity data to the SARS-CoV-2 virus in patients who died from a new coronavirus infection with elevated serum Ig class G and M levels and negative PCR. Material and methods. An analysis of clinical, laboratory, and pathomorphological changes was conducted in 33 autopsy observations of patients who died during the first half of 2021 in the specialized non-infectious departments of the City Clinical Hospital No. 31 named after Academician G.M. Savelyeva with an elevated content of serum Ig class G and M in the blood Results. Despite the negative PCR, elevated concentrations of Ig to SARS-CoV-2 proteins were detected in the blood of patients: IgG 0.31 — 532.56 OCE (Me 109.33 OCE), IgM 0.14 — 16.8 U / ml (Me 0.62 IU / ml). At an IgG concentration of 0.31-109.33 OCE in the lungs, an exudative phase of diffuse alveolar damage (DAD) was described, in the IgG range of 122.57-158.72 OCE, exudative-proliferative DAD was described, at IgG values 207.2-532.56 OCE, the proliferative phase of DAD occurred Conclusion. The study revealed a sequence of pathological changes in the lungs, depending on the serum IgG concentration, characteristic of DAP. The findings confirm the multifaceted nature of the novel coronavirus infection
18 August 2026 in Neurology, Neuropsychiatry, Psychosomatics
Objective: to assess the impact of cyclobenzaprine therapy in real-world clinical practice on the severity of pain, functional capacity and the time taken to return to work in patients with non-specific back and neck pain, as well as to evaluate the drug's safety profile. Material and methods. The multicentre study included 997 patients (full analysis set, FAS) aged 18 years or older, of whom 976 completed the study according to protocol – per-protocol (PP) population. Patients received Reloprim (cyclobenzaprine) at a dose of 5, 7.5 or 10 mg three times daily for up to 14 days. The primary endpoint was the change in functional limitations as assessed by the Roland–Morris Disability Questionnaire (RMDQ). Results. The baseline RMDQ score was 12.52±5.57. By day 5, it had decreased significantly to 7.18±4.53, and by the end of the study to 1.89±2.42 (p<0.001). Pain intensity (baseline 6.79±1.46 points) decreased by 2.98±1.3 points by day 5 and by 5.85±1.72 points by the end of the observation period (p<0.001). The number of patients temporarily unable to work was reduced by almost half (from 10.75 to 5.94). The need for additional doses of non-steroidal anti-inflammatory drugs (NSAIDs) was reduced by more than half. Conclusion. The use of cyclobenzaprine as part of a comprehensive treatment regimen for non-specific back and neck pain in real-world clinical practice is associated with a statistically significant reduction in the severity of pain and functional limitations as early as the first few days of treatment, with the effect continuing to improve by the end of the observation period.